Sep 24 |
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
|
Sep 24 |
Biogen, UCB get the lupus data they’ve waited two decades for
|
Sep 23 |
Update: Wedbush Cuts Biogen's Price Target to $205 From $210 Due to Lack of 'Clear-Cut Revenue Driver', Keeps Neutral Rating
|
Sep 23 |
Forecasting The Future: 20 Analyst Projections For Biogen
|
Sep 20 |
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™
|
Sep 18 |
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
|
Sep 16 |
Hope remains that Roche’s prasinezumab can overcome recent string of failures in Parkinson’s disease
|
Sep 13 |
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
|
Sep 12 |
Healthcare Stocks Have Popped. Consider These 2 That Haven’t.
|
Sep 12 |
Biogen Board Appoints Two New Independent Directors
|